fenebrutinib (GDC-0853) - Roche
|
Xolair (omalizumab) - Roche, Novartis
|
Nucala (mepolizumab) - GSK
|
ligelizumab (QGE 031) - Novartis
|
antolimab (AK002) - Allakos
|
Dupixent (dupilumab) - Sanofi, Regeneron
|
Cinqair (reslizumab) - Merck (MSD), UCB, Teva
|
Fasenra (benralizumab) - AstraZeneca
|
UB-221 - United BioPharma
|
remibrutinib (LOU064) - Novartis
|